comparemela.com

Latest Breaking News On - Nkarta inc - Page 1 : comparemela.com

Nkarta (NASDAQ:NKTX) Given New $13 00 Price Target at Needham & Company LLC

Nkarta (NASDAQ:NKTX) Given New $13 00 Price Target at Needham & Company LLC
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Nkarta (NASDAQ:NKTX) PT Lowered to $15 00

Nkarta (NASDAQ:NKTX) PT Lowered to $15 00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Small-Cap Firm Century Therapeutics Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing - Century Therapeutics (NASDAQ:IPSC)

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc (NKTX) on Behalf of Investors

Glancy Prongay & Murray LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nkarta, Inc. investors concerning the Company’s.

The Law Offices of Frank R Cruz Announces Investigation of Nkarta, Inc (NKTX) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Nkarta, Inc. on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.